These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34292643)

  • 1. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
    Harris S; Comi G; Cree BAC; Arnold DL; Steinman L; Sheffield JK; Southworth H; Kappos L; Cohen JA;
    Eur J Neurol; 2021 Nov; 28(11):3722-3730. PubMed ID: 34292643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
    DeLuca J; Schippling S; Montalban X; Kappos L; Cree BAC; Comi G; Arnold DL; Hartung HP; Sheffield JK; Liu H; Silva D; Cohen JA
    Mult Scler Relat Disord; 2021 Feb; 48():102673. PubMed ID: 33454584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
    Kuhle J; Chitnis T; Banwell B; Tardieu M; Arnold DL; Rawlings AM; Geertsen SS; Lublin AL; Saubadu S; Truffinet P; Kappos L
    Mult Scler; 2023 Mar; 29(3):385-394. PubMed ID: 36632983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-β-1a (Avonex
    Koscielny V
    Neurodegener Dis Manag; 2018 Jun; 8(3):141-142. PubMed ID: 29943693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
    Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L;
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients.
    Szilasiová J; Rosenberger J; Fedičová M; Mikula P; Urban P; Gdovinová Z; Vitková M; Hanes J; Stevens E
    Eur Neurol; 2021; 84(4):272-279. PubMed ID: 34034261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis.
    Cohan S; Tencer T; Arndorfer S; Zhu X; Zivkovic M; Kumar J
    Mult Scler Relat Disord; 2021 Jul; 52():102972. PubMed ID: 33979770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW; Cohen JA; Comi G; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Havrdova EK; Cree BAC; Minton N; Sheffield JK; Ding N; Kappos L
    Mult Scler Relat Disord; 2021 Jun; 51():102844. PubMed ID: 33892317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
    Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
    Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis.
    Szilasiova J; Mikula P; Rosenberger J; Fedicova M; Urban P; Frigova L; Vitkova M; Gdovinova Z; Hanes J; Stevens E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):304-311. PubMed ID: 34092793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Szilasiová J; Mikula P; Rosenberger J; Fedičová M; Gdovinová Z; Urban P; Frigová L
    Mult Scler; 2021 Nov; 27(13):2023-2030. PubMed ID: 33635154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis.
    Fedičová M; Mikula P; Gdovinová Z; Vitková M; Žilka N; Hanes J; Frigová L; Szilasiová J
    Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241097
    [No Abstract]   [Full Text] [Related]  

  • 20. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L; Paul F
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.